De novo synthetic antimicrobial peptide design with a recurrent neural network
Protein Science · 2024
DOI: 10.1002/pro.5088 ↗Kurz gefasst
Fachartikel in der Zeitschrift Protein Science, 2024. Verfasst von Chenkai Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia, Canada. Hauptthemen laut MEDLINE: Neural Networks, Computer, Antimicrobial Peptides. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Genome BC, Genome Canada, Investment Agriculture Foundation of BC.
Abstract (Originalsprache)
Antibiotic resistance is recognized as an imminent and growing global health threat. New antimicrobial drugs are urgently needed due to the decreasing effectiveness of conventional small‐molecule antibiotics. Antimicrobial peptides (AMPs), a class of host defense peptides, are emerging as promising candidates to address this need. The potential sequence space of amino acids is combinatorially vast, making it possible to extend the current arsenal of antimicrobial agents with a practically infinite number of new peptide‐based candidates. However, mining naturally occurring AMPs, whether directly by wet lab screening methods or aided by bioinformatics prediction tools, has its theoretical limit regarding the number of samples or genomic/transcriptomic resources researchers have access to. Further, manually designing novel synthetic AMPs requires prior field knowledge, restricting its throughput. In silico sequence generation methods are gaining interest as a high‐throughput solution to the problem. Here, we introduce AMPd‐Up, a recurrent neural network based tool for de novo AMP design, and demonstrate its utility over existing methods. Validation of candidates designed by AMPd‐Up through antimicrobial susceptibility testing revealed that 40 of the 58 generated sequences possessed antimicrobial activity against Escherichia coli and/or Staphylococcus aureus . These results illustrate that AMPd‐Up can be used to design novel synthetic AMPs with potent activities.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia, Canada.
- Bioinformatics Graduate Program, University of British Columbia, Vancouver, British Columbia, Canada.
- Public Health Laboratory, British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada.
- Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
- Department of Chemistry and the Centre for Advanced Materials and Related Technology, University of Victoria, Victoria, British Columbia, Canada.
- Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada.
ORCID-Profile: Chenkai Li
Förderung
- Genome BC
- Genome Canada
- Investment Agriculture Foundation of BC
- Genome British Columbia
Zitieren
APA
Li, C., Sutherland, D., Richter, A., Coombe, L., Yanai, A., Warren, R. L., Kotkoff, M., Hof, F., Hoang, L. M. N., Helbing, C. C., & Birol, I. (2024). De novo synthetic antimicrobial peptide design with a recurrent neural network. Protein Science. https://doi.org/10.1002/pro.5088
Vancouver
Li C, Sutherland D, Richter A, Coombe L, Yanai A, Warren RL, et al. De novo synthetic antimicrobial peptide design with a recurrent neural network. Protein Science. 2024. doi:10.1002/pro.5088
BibTeX
@article{Li2024,
author = {Li, Chenkai and Sutherland, Darcy and Richter, Amelia and Coombe, Lauren and Yanai, Anat and Warren, René L and Kotkoff, Monica and Hof, Fraser and Hoang, Linda M N and Helbing, Caren C and Birol, Inanc},
title = {De novo synthetic antimicrobial peptide design with a recurrent neural network},
journal = {Protein Science},
year = {2024},
doi = {10.1002/pro.5088}
}
EUVIMED